Zydus, today announced that it has received permission to initiate the Phase 1 clinical trial of ZYIL1, a novel oral small molecule NLRP3 inhibitor candidate.... Dec 07
Enumeration of Circulating Endothelial Cells (CECs) with CELLSEARCH platform may offer a new tool for investigating the role of the damaged endothelium in SARS-CoV-... Apr 28
-Advertisements-